Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2007-07-24
2007-07-24
Rawlings, Stephen L. (Department: 1643)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C530S387300, C530S388100, C530S391700
Reexamination Certificate
active
11241721
ABSTRACT:
The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases. The anti-cancer antibodies can be conjugated to red blood cells obtained from that patient and re-infused for treatment of metastases based upon the recognition that metastatic cancers are usually well vascularized and the delivery of anti-cancer antibodies by red blood cells can have the effect of concentrating the antibodies at the site of the tumor.
REFERENCES:
patent: 4172124 (1979-10-01), Koprowski et al.
patent: 4861581 (1989-08-01), Epstein et al.
patent: 4939240 (1990-07-01), Chu
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5693363 (1997-12-01), Kuroda et al.
patent: 5750102 (1998-05-01), Eisenbach et al.
patent: 5780033 (1998-07-01), Torchilin et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5849876 (1998-12-01), Linsley et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5869268 (1999-02-01), Kudo et al.
patent: 6180357 (2001-01-01), Young et al.
patent: 0 222 360 (1987-05-01), None
patent: WO 94/18345 (1994-08-01), None
C. Badger et al., “Prospects for Monoclonal Antibody therapy of Leukimia and Lymphoma”, Cancer vol. 58, (1986) pp. 584-589.
A. Begg et al., “Rapid Fluorescence-based Assay for Radiosensitivity and Chemoscensivity Testing in mammalian Cells in Vitro”, Cancer research, vol. 49, (1986) pp. 565-569.
E. Boven et al., “Monoclonal Antibodies in Cancer Treatment: Where Do We Stand After 10 Years?”, Radiotherapy & Oncology, vol. 5 (1986) pp. 109-117.
A. Costa et al., “Implications of Disaggggregation Procedures on Biological Representation of Human Solid Tumours”, Cell Tissue Kinet, vol. 20, (1987) pp. 171-180.
Cruse et al., Illustrated Dictionary of Immunology, CRC Press, (1995)p. 280.
S. Dairkee et al., “Partial Enxymatic Degredation of Stroma Allows Enrichment and Expansion of Primary Breast Tumor Cells”, Cancer Res. vol. 57. (1997) pp. 1590-1596.
R. Dillman, “Antibodies as Cytotoxic Therapy”, Journal of Clinical Oncology, vol. 12, (1994) pp. 1497-1515.
R. Dillman, “Monoclonal Antibodies for Treating Cancer”, Annals of Internal Medecine, vol. 111 (1989)pp. 592-603.
M. Disis et al., “Her-2
eu Protein: A Target for Antigen-Specicfc Immunotherapy of Human Cancer”, Advances in Cancer Research, vol. 71 (1997) pp. 343-371.
H. Dvorak et al., “Structure of Solid Tumors and their Vasculature: Implications for Therapy With Monoclonal Antibodies”, Cancer Cells, vol. 3 (1991) pp. 77-85.
S. Engelhohn et al., “Disaggregation of Human Solid Tumours by Combined Mechanical and Enzymatic methods”, Br. J. Cancer vol. 51 (1985) pp. 93-98.
A. Epsstein et al., “Two New Monoclonal Antibodies: Lym-1 and Lyn02, Reactive with Human B-Lymphocytes and Derived Tumours, with Immunodiagnostic and Immunotherapeutic Potential”, Cancer research vol. 47 (1987) pp. 830-840.
K. Foon, “Biological Therapy of Cancer”, Breast Cancer Research & Treatmetn vol. 7 (1986) pp. 5-14.
B. Franzen et al., “Nonenzymatic Extraction of Cells from Clnical Tumor Material for Analysis of Gene Expression by Two-Dimensional Polyacrylaamide gel Electrophoresis”, Electrophoresis, vol. 14 (1993) pp. 1045-1053.
D. Harris et al., “Serotherapy of Cancer”, Seminars in Oncology, vol. 16 (1989) pp. 180-198.
Herlyn et al., “Monoclonal Anticolon Carcinoma Antibodies in Complement-Dependent Cytoxicity”, Int. J. Cancer 27, (1981); pp. 769-774.
Holz E et al., “Antibody-Based immunotherapeutic Strategies in Colorectal Cancer”, Recent Results in Cancer Research, vol. 142 (1996) pp. 381-400.
Horoszewicz et al., “Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients”, Anticancer Research 7, (1987) pp. 927-936.
V. Kravstov et al., “Automated monitoring of Apoptosis in Suspension Cell Cultures”, Laboratory Investigation, vol. 74 (1996) pp. 557-570.
A. Knuth et al, “ADCC reactivity of human melanoma cells with mouse monoclonal antibodies”, Proc. Am. Assoc. Cancer Res., 25:1005 (May 1984).
Takahashi Miyoko
Young David S. F.
Arius Research Inc.
Duffy Brad
McHale & Slavin P.A.
Rawlings Stephen L.
LandOfFree
Individualized anti-cancer antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Individualized anti-cancer antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Individualized anti-cancer antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3735633